Docivyx

Docivyx

(DOCETAXEL INJECTION)

20 mg/2 mL (10 mg/mL)
NDC: 83831-101-02
80 mg/8 mL (10 mg/mL)
NDC: 83831-102-08
160 mg/16 mL (10 mg/mL)
NDC: 83831-103-16
20 mg/2 mL
10 mg/mL
NDC 83831-101-02
80 mg/8 mL
10 mg/mL
NDC 83831-102-08
160 mg/16 mL
10 mg/mL
NDC 83831-103-16

Indicated for use in breast cancer,
non-small cell lung cancer, prostate cancer,
gastric adenocarcinoma, head and neck cancer*

*DOCIVYX™ is a microtubule inhibitor indicated for: Breast cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. Non-small cell lung cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC. Castration-resistant prostate cancer (CRPC): with prednisone in metastatic CRPC. Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction. Squamous cell carcninoma of the head and neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN.

SUPPLIED AS A SOLUTION

Simplifying patient access, providing comprehensive support

For additional support, speak with an AVYXASSIST™
Patient Access Specialist today

Call 866-939-8927 or Fax 833-852-3420
Monday through Friday, 8:00 AM - 8:00 PM ET
Please call AVYXASSIST™ for assistance with other languages. Translation services are available.

The Site You are About to Enter is intended for
US healthcare professionals only.